3-Ethynyl-3-hydroxy-1-methylpyrrolidin-2-one → (+/-)-10-((3-Hydroxy-1-methyl-2-oxopyrrolidin-3-yl)ethynyl)-5,6-dihydrobenzo[f]imidazo[1,2-d][1,4]oxazepine-2-carboxamide
반응식
Br[C:2]1[CH:3]=[CH:4][C:5]2[O:11][CH2:10][CH2:9][N:8]3[CH:12]=[C:13]([C:15]([NH2:17])=[O:16])[N:14]=[C:7]3[C:6]=2[CH:18]=1.[C:19]([C:21]1([OH:28])[CH2:25][CH2:24][N:23]([CH3:26])[C:22]1=[O:27])#[CH:20]>>[OH:28][C:21]1([C:19]#[C:20][C:2]2[CH:3]=[CH:4][C:5]3[O:11][CH2:10][CH2:9][N:8]4[CH:12]=[C:13]([C:15]([NH2:17])=[O:16])[N:14]=[C:7]4[C:6]=3[CH:18]=2)[CH2:25][CH2:24][N:23]([CH3:26])[C:22]1=[O:27]참가 물질
3
실험 절차
Similar to as described in General Procedure G, 10-bromo-5,6-dihydrobenzo[f]imidazo[1,2-d][1,4]oxazepine-2-carboxamide was reacted with 3-ethynyl-3-hydroxy-1-methylpyrrolidin-2-one (WO2009/158011A1) to give the titled compound as a light yellow solid (17 mg, 7%).
출처 및 근거
- ORD 기록
- ord-1a66b5a200a040dfb0b580fdd84d8514
- 출처 데이터셋
- uspto-grants-2015_05
- 특허 번호
- US09034866B2
반응 노트
불러오는 중…